299 related articles for article (PubMed ID: 26505995)
1. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Gill SJ; Travers J; Pshenichnaya I; Kogera FA; Barthorpe S; Mironenko T; Richardson L; Benes CH; Stratton MR; McDermott U; Jackson SP; Garnett MJ
PLoS One; 2015; 10(10):e0140988. PubMed ID: 26505995
[TBL] [Abstract][Full Text] [Related]
2. PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Engert F; Schneider C; Weiβ LM; Probst M; Fulda S
Mol Cancer Ther; 2015 Dec; 14(12):2818-30. PubMed ID: 26438158
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
4. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ
Clin Cancer Res; 2015 Feb; 21(4):819-32. PubMed ID: 25500058
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview.
Adibi A; Tokat ÜM; Özgü E; Aydın E; Demiray İ; Demiray M
Ther Adv Med Oncol; 2023; 15():17588359231213841. PubMed ID: 38107827
[TBL] [Abstract][Full Text] [Related]
7. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
Liu X; Shi Y; Guan R; Donawho C; Luo Y; Palma J; Zhu GD; Johnson EF; Rodriguez LE; Ghoreishi-Haack N; Jarvis K; Hradil VP; Colon-Lopez M; Cox BF; Klinghofer V; Penning T; Rosenberg SH; Frost D; Giranda VL; Luo Y
Mol Cancer Res; 2008 Oct; 6(10):1621-9. PubMed ID: 18922977
[TBL] [Abstract][Full Text] [Related]
9. Ewing sarcoma protein promotes dissociation of poly(ADP-ribose) polymerase 1 from chromatin.
Lee SG; Kim N; Kim SM; Park IB; Kim H; Kim S; Kim BG; Hwang JM; Baek IJ; Gartner A; Park JH; Myung K
EMBO Rep; 2020 Nov; 21(11):e48676. PubMed ID: 33006225
[TBL] [Abstract][Full Text] [Related]
10. XRCC1 prevents toxic PARP1 trapping during DNA base excision repair.
Demin AA; Hirota K; Tsuda M; Adamowicz M; Hailstone R; Brazina J; Gittens W; Kalasova I; Shao Z; Zha S; Sasanuma H; Hanzlikova H; Takeda S; Caldecott KW
Mol Cell; 2021 Jul; 81(14):3018-3030.e5. PubMed ID: 34102106
[TBL] [Abstract][Full Text] [Related]
11. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
[TBL] [Abstract][Full Text] [Related]
12. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
Brenner JC; Feng FY; Han S; Patel S; Goyal SV; Bou-Maroun LM; Liu M; Lonigro R; Prensner JR; Tomlins SA; Chinnaiyan AM
Cancer Res; 2012 Apr; 72(7):1608-13. PubMed ID: 22287547
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
Gottipati P; Vischioni B; Schultz N; Solomons J; Bryant HE; Djureinovic T; Issaeva N; Sleeth K; Sharma RA; Helleday T
Cancer Res; 2010 Jul; 70(13):5389-98. PubMed ID: 20551068
[TBL] [Abstract][Full Text] [Related]
14. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE
Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448
[TBL] [Abstract][Full Text] [Related]
15. Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor.
Yamasaki H; Miyamoto M; Yamamoto Y; Kondo T; Watanabe T; Ohta T
Genes Cells; 2016 Aug; 21(8):852-60. PubMed ID: 27353471
[TBL] [Abstract][Full Text] [Related]
16. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
[TBL] [Abstract][Full Text] [Related]
17. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.
Boulton S; Kyle S; Durkacz BW
Carcinogenesis; 1999 Feb; 20(2):199-203. PubMed ID: 10069454
[TBL] [Abstract][Full Text] [Related]
18. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
[TBL] [Abstract][Full Text] [Related]
19. Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells.
Wang H; Zhang S; Song L; Qu M; Zou Z
Oncogene; 2020 Apr; 39(14):2905-2920. PubMed ID: 32029902
[TBL] [Abstract][Full Text] [Related]
20. XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA.
Hirota K; Ooka M; Shimizu N; Yamada K; Tsuda M; Ibrahim MA; Yamada S; Sasanuma H; Masutani M; Takeda S
Genes Cells; 2022 May; 27(5):331-344. PubMed ID: 35194903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]